Life Scientist > Biotechnology

Fast composter for city waste

23 November, 2005 by Graeme O'Neill

Researchers from the Environmental Biotechnology Cooperative Research Centre (EBCRC) have successfully tested a, self-sustaining process that rapidly composts municipal solid wastes.


Norwood commences phase II cancer vaccine trial

21 November, 2005 by Graeme O'Neill

Melbourne meditech Norwood Immunology (AIM:NIM) has recruited the first of 100 post-surgical melanoma patients into a phase II clinical trial of its thymus-rejuvenating technology, using the gonadotrophin releasing hormone (GNRH) analogue Lupron Depot.


National bioprospecting regulations released

21 November, 2005 by Ruth Beran

The Australian government has released new national environmental regulations to control 'bioprospecting' -- the search for new chemicals in living things that will have some medical or commercial use.


CSIRO abandons GM pea project

18 November, 2005 by Graeme O'Neill

CSIRO Plant Industry researchers have abandoned a project to develop a genetically modified field pea with resistance to the pea weevil, Bruchus pisorum.


Novogen pleased by cancer drug results

18 November, 2005 by Ruth Beran

Trials of Novogen's (ASX:NRT) anti-cancer drug phenoxodiol have shown it significantly delays tumour progression in men suffering from late-stage hormone refractory prostate cancer and produces anti-cancer responses in women with cervical cancer.


OPINION: Taking advantage of our clinical strengths

18 November, 2005 by Graeme Blackman

Australia, take a bow -- you've proved you can compete in the global clinical trials market. But let's not get too complacent, writes Graeme Blackman.


REPORT: How we score on pharma R&D

18 November, 2005 by Ruth Beran

Ruth Beran wraps up a recent report that gives Australia a high rating against other major centres of pharma R&D.


Aust CROs tell of boom in clinical trials work

18 November, 2005 by Ruth Beran

Ruth Beran spoke with Australian contract research organisations and found that there is strong demand for Australian clinical trials, both from within Australia and also from overseas.


New research shows Aussie lizard bites can really hurt

17 November, 2005 by Graeme O'Neill

Australian venom researchers have uncovered a 200-million year old secret: Australia's goannas and bearded dragons, Indonesia's giant Komodo dragon, and their iguana cousins, are more closely related to snakes than to other lizards -- and they're venomous.


Metabolic reports successful phase I trials

16 November, 2005 by Graeme O'Neill

Melbourne biopharma Metabolic (ASX:MBP) has announced plans to take its ACV1 conotoxin analgesic into phase IIa clinical trial in volunteers with chronic neuropathic pain next year.


Phosphagenics aims to raise $11.25m

15 November, 2005 by Helen Schuller

Melbourne's Phosphagenics (ASX:POH, AIM:PSG) is planning to raise AUD$11.25 million via a share placement to fund its core R&D program.


CyGenics to team with Johns Hopkins

15 November, 2005 by Helen Schuller

Cell therapy company CyGenics (ASX:CYN) and Johns Hopkins University School of Medicine have entered into a collaborative research agreement as part of a pre-clinical study directed at a new treatment strategy for patients with acute myeloid leukaemia (AML).


Starpharma raises $15m

15 November, 2005 by Helen Schuller

Melbourne drug developer Starpharma (ASX:SPL) has successfully raised AUD$12 million through an institutional placement at $0.51 and an additional $3 million following an underwritten share purchase plan.


Study supports Prima vaccine effectiveness

15 November, 2005 by Graeme O'Neill

A research report in the international journal Vaccine this month has confirmed the immunity-boosting potency of Prima Biomed's (ASX:PRR) novel DCtag adjuvant technology for veterinary vaccines.


Xenome builds team, strengthens US ties

11 November, 2005 by Graeme O'Neill

Unlisted Brisbane biotech Xenome is making a strong push into San Diego, hub of the US West Coast biotech industry, in pursuit of venture capital and big pharma partners to develop its long and diverse pipeline of conotoxin peptides from the venom of Australian cone shells.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd